CD274 and ovarian carcinoma: Whilst the regulation of DNA methylation and histone modifications in PD-L1 expression has been explored, a novel epigenetic drug, JQ1, a selective bromodomain inhibitor (BETi), was corroborated to suppress PD-L1 expression in ovarian cancer to restore cytotoxic T cell responses (93).